BNGO

Bionano Genomics Inc

Add to Watchlist

Advanced Chart

3.836

-0.014(-0.360%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

3.9471

Open

3.870

VWAP

3.86

Vol

22.41K

Mkt Cap

11.90M

Low

3.800

Amount

86.41K

EV/EBITDA(TTM)

Total Shares

69.11M

6.26M

EV/OCF(TTM)

P/S(TTM)

0.16

Bionano Genomics, Inc. is a genomics company, which provides optical genome mapping (OGM) for genome analysis. The Company offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. It markets and sells the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

8.08M

+33.1%

7.01M

-9.75%

6.25M

-28.73%

Estimates Revision

The market is revising Downward the revenue expectations for Bionano Genomics, Inc. (BNGO) for FY2025, with the revenue forecasts being adjusted by -18.52% over the past three months. During the same period, the stock price has changed by -26.52%.

Revenue Estimates for FY2025

Revise Downward

-18.52%

In Past 3 Month

Stock Price

Go Down

-26.52%

In Past 3 Month

3 Analyst Rating

82.51% Upside

Wall Street analysts forecast BNGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNGO is 7.00 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

82.51% Upside

Current: 3.836

Low

4.00

Averages

7.00

High

10.00

82.51% Upside

Current: 3.836

Low

4.00

Averages

7.00

High

10.00

HC Wainwright & Co.

Yi Chen

Strong Buy

Initiates

$10

2025-04-09

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10

2025-04-09

Initiates

Strong Buy

Reason

Scotiabank

Sung Ji Nam

Hold

Maintains

$1 → $4

2025-04-02

Reason

Scotiabank

Sung Ji Nam

Price Target

$1 → $4

2025-04-02

Maintains

Hold

Reason

Scotiabank raised the firm's price target on Bionano Genomics to $4 from $1 and keeps a Sector Perform rating on the shares. Despite the challenging macroeconomic environment in 2024, there were "bright spots" for the company, such as double-digit growth for Consumables and Software revenues, the analyst tells investors. The firm is favoring the sidelines until it has better visibility into the company's near- to medium-term growth potential.

Ladenburg Thalmann

Jeff Cohen

Strong Buy

Hold

Downgrades

n/a

2024-11-15

Reason

Ladenburg Thalmann

Jeff Cohen

Price Target

n/a

2024-11-15

Downgrades

Strong Buy

Hold

Reason

Ladenburg analyst Jeffrey Cohen downgraded Bionano Genomics to Neutral from Buy.

BTIG

Mark Massaro

Strong Buy

Hold

Downgrades

n/a

2024-09-10

Reason

BTIG

Mark Massaro

Price Target

n/a

2024-09-10

Downgrades

Strong Buy

Hold

Reason

Scotiabank

Sung Ji Nam

Buy

Hold

Downgrades

$6 → $1

2024-08-28

Reason

Scotiabank

Sung Ji Nam

Price Target

$6 → $1

2024-08-28

Downgrades

Buy

Hold

Reason

BTIG

Mark Massaro

Strong Buy

Maintains

$3 → $2

2024-05-16

Reason

BTIG

Mark Massaro

Price Target

$3 → $2

2024-05-16

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bionano Genomics Inc (BNGO.O) is -0.46, compared to its 5-year average forward P/E of -6.98. For a more detailed relative valuation and DCF analysis to assess Bionano Genomics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.98

Current PE

-0.46

Overvalued PE

3.24

Undervalued PE

-17.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.36

Current EV/EBITDA

-2.44

Overvalued EV/EBITDA

5.32

Undervalued EV/EBITDA

-18.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

23.59

Current PS

0.37

Overvalued PS

61.75

Undervalued PS

-14.56

Financials

Annual

Quarterly

FY2024Q4

YoY :

-23.86%

8.16M

Total Revenue

FY2024Q4

YoY :

-52.70%

-11.80M

Operating Profit

FY2024Q4

YoY :

-54.15%

-20.13M

Net Income after Tax

FY2024Q4

YoY :

-81.50%

-12.22

EPS - Diluted

FY2024Q4

YoY :

-78.69%

-6.50M

Free Cash Flow

FY2024Q4

YoY :

+84.08%

41.86

Gross Profit Margin - %

FY2024Q4

YoY :

-36.16%

-224.28

FCF Margin - %

FY2024Q4

YoY :

-39.78%

-246.54

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

1.1M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BNGO News & Events

Events Timeline

2025-05-02 (ET)

2025-05-02

09:36:19

Bionano announces publication on expert recommendations for OGM integration

2025-04-23 (ET)

2025-04-23

08:11:59

Bionano Genomics announces publication on OGM

2025-04-08 (ET)

2025-04-08

08:21:31

Bionano announces French publication of method for analysis of MM by OGM

News

9.5

05-07Yahoo Finance

PinnedBionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

9.0

05-02Newsfilter

International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers

4.0

04-09Benzinga

HC Wainwright & Co. Initiates Coverage On Bionano Genomics with Buy Rating, Announces Price Target of $10